A detailed history of Claret Asset Management Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Claret Asset Management Corp holds 1,494 shares of NBIX stock, worth $171,839. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,494
Holding current value
$171,839
% of portfolio
0.03%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$111.62 - $139.44 $166,760 - $208,323
1,494 New
1,494 $204,000
Q1 2024

Apr 29, 2024

SELL
$130.4 - $143.74 $14,865 - $16,386
-114 Reduced 7.28%
1,451 $200,000
Q4 2023

Feb 12, 2024

BUY
$106.07 - $132.76 $165,999 - $207,769
1,565 New
1,565 $206,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Claret Asset Management Corp Portfolio

Follow Claret Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Claret Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Claret Asset Management Corp with notifications on news.